Fourth, we did not evaluate the survival advantage associated with COP or compare the distributions of breast cancer stage and ER/PR/HER2 status between patients with and without COP because they are out of the scope of the present study and the databases do not contain the some of the information. This evidence concerns the gene ERBB2 and breast cancer.